I started my breast cancer treatment under the care of one oncologist. And then in a search for more warmth and compassion, I landed in a new relationship with a new oncologist. He offered me just what I was seeking. Plus something I didn't expect.

My new oncologist offered me a new treatment plan -- a new course of action that better suited my specific disease.

U.S. researchers reported yesterday that breast cancer patients were urged to change their treatment plan more than half the time when they received a second opinion from a multidisciplinary panel of surgeons, radiation oncologists, medical oncologists, radiologists, and pathologists.

Researchers at the University of Michigan Comprehensive Cancer Center believe second-opinion changes are a result of different interpretations of breast imaging and pathology results, consideration of new techniques and treatments, discovery of undiagnosed second cancers, and emerging medical research.

It wasn't a formal multidisciplinary team that delivered me a new, better opinion for my own cancer care. It was one man, who merged instinct and science and then consulted a well-know oncologist friend who agreed with the approach I ended up following.

I am thankful for everything I gained from my second opinion -- the warmth, the compassion, the treatment plan that has served me well for two years.

A review was done by an international panel of experts of literature concerning chronic myeloid leukemia (CML) for the recommendation of treatment options. The panel included ten members that reviewed 194 papers on CML written since 1998.

The article was recently published in the journal Blood. Gleevec (imatinib mesylate) has become a standard treatment for Philadelphia chromosome-positive CML. Specific guidelines for the use of Gleevec in the treatment of CML have recently been compiled.

• All newly diagnosed patients should be treated with 400 mg of Gleevec per day.
• Patients who do not respond to Gleevec should be treated with higher doses, an allogeneic stem cell transplantation, or experimental therapy. This experimental therapy could include agents designed to over come resistance to Gleevec.

Responses to treatment can be determined by several laboratory tests. Talk to your physician about specific details regarding responses to Gleevec.

Five years ago, when Michael Dunn's seven-year-old son Steven woke one morning with a swollen left eye, he took him to the emergency room thinking they would come home with eye drops for Steven. Instead, Steven became the 33rd known case of rhabdomyosarcoma, a cancer striking soft body tissue, that had no long-term survivors over the age of 20.

Enter artist Connie Douglas. While doing some work in the Dunn home, she was in awe of Steven's spirit as he battled cancer that would most likely steal his life before he reached adulthood. Inspired by Steven, she contacted Phoenix Children's Hospital, with a proposal to create and donate artwork for the children who visited or stayed at the hospital.

The art project turned into nine wall story panels, and within each painted panel are hidden Shnnoogles. A Shnnoogle, which stands for caring and sharing, hugging and snuggling, giving in goodness and action, are furry snowball creatures with big round eyes. As children look at the panels, they search for the hidden Shnnoogles.

While Douglas was painting the panels, she was diagnosed with MS. To be equally inspired by Arizona Republic Kathleen Quilligan's feature Artist hopes Shnnoogles bring comfort to hospitalized kids, to find out how Steven and Connie are doing, and the book she plans to write, go here.

Reuters has just issued an update on Eli Lilly's announcement that the U.S. Food and Drug Administration, FDA, approved the use of Gemzar in the treatment of recurrent ovarian cancer, questioning why the company omitted information that the FDA approval goes against the advice of an FDA advisory panel earlier this year that strongly recommended against approval of the drug for this use.

The FDA approved use of Gemzar in combination with carboplatin, in chemotherapy treatment for women with advanced ovarian cancer that has relapsed at least six months after initial therapy. The reason the FDA advisory panel voted against the approval of the use of Gemzar in combination with carboplatin, were due to questions raised about Lilly's trial data and the way the company conducted the 356-person clinical study. The panel was concerned that patients in the late-stage clinical trial failed to survive longer than those taking carboplatin alone. The FDA went ahead and approved it after the drug company provided additional information.

What needs to be made clear is that Gemzar does not seem to prolong the life of women with recurrent ovarian cancer, and the drug company is only stating that Gemzar provides longer progression-free survival than patients taking carboplatin alone. Progression-free survival measures the time before the disease recurs or worsens.

According to Reuters, when a spokesperson for Lilly was asked why they did not mention in its release that the FDA advisory panel had voted against the approval of Gemzar, or the drug's failure to prolong life, he said, "I'm not sure that needed to be the focus."

For a health-informed public that is beginning to demand more nutrition and less fat in the food they are served -- fast food is falling out of its once favored position of popularity as a quick meal for kids. Who doesn't think that McDonald's and the golden arches are the unofficial defining symbol for fast food?

In response to the perception that fast food is not linked to good health, along with the negative image resulting from the book and movie Fast Food Nation -- and now the publication of a children's book Chew On This, which is co-written by Fast Food Nation author Eric Schlosser -- McDonald's has announced the creation of a Global Moms Panel. Nine women from six countries will advise the company on balanced and active lifestyle initiatives, restaurant communications and children's well-being.

Translation? McDonald's wants to find out how to market to moms who are interested in their children living long healthy lives free from obesity and the nutrition-deficient food that can increase the risks for major disease later in life, like cancer. Which has the potential for being a good thing if McDonalds does offer healthier food as a result of the recommendations from moms. If it's just a public relations campaign to improve a business image then I believe the public will see through it and the effort will backfire. According to Mary Dillon, McDonald's global chief marketing officer, "We want to become the best ally we can for moms and a true partner in the well-being of families everywhere." Time will tell.